Lesson 5 of 5 · 30 min

Clozapine: Treatment-Resistant Schizophrenia & ANC Monitoring

Learning objectives

Define the indications for clozapine
Apply ANC-based monitoring principles
Recognize myocarditis, seizures, constipation and metabolic risks

Clozapine is the antipsychotic with the strongest evidence for treatment-resistant schizophrenia and reduces suicidal behavior in schizophrenia and schizoaffective disorder.

Severe neutropenia is a key risk; absolute neutrophil count (ANC) monitoring is required according to current labeling and program requirements. Always check the most current regulatory guidance — requirements have changed over time.

Other serious risks: myocarditis/cardiomyopathy (often early), seizures (dose-related), severe constipation/ileus, orthostatic hypotension, sialorrhea, and significant metabolic effects.

Key points

For treatment-resistant schizophrenia (failed ≥2 adequate trials)
ANC monitoring is essential
Smoking induces CYP1A2 — quitting smoking can raise clozapine levels

Exam pearls

◆ Fever, chest pain, tachycardia in first weeks → think myocarditis
◆ Constipation on clozapine can be life-threatening — ask every visit
◆ Patient stops smoking → levels rise → toxicity risk

Educational content for exam preparation; verify dosing and monitoring with current prescribing information. References: [APA 7 placeholder — to be supplied by author].

Lesson check

Question 1 · clozapine

Three weeks after starting clozapine, a patient has fever, chest pain and tachycardia. The PRIORITY concern is:

Question 2 · clozapine

A patient stable on clozapine quits smoking. What is the expected effect?

Question 3 · clozapine

Which adverse effect of clozapine should be asked about at EVERY visit because it can be life-threatening?